Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01358825
Other study ID # 115375
Secondary ID 2011-000943-26
Status Completed
Phase Phase 4
First received
Last updated
Start date May 30, 2011
Est. completion date July 15, 2011

Study information

Verified date January 2021
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess antibody persistence in infants who received three doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix-IPV/Hib™ (DTPa-IPV/Hib) at 3, 5 and 11 months of age in study NCT00307034.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date July 15, 2011
Est. primary completion date July 15, 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 6 Years
Eligibility Inclusion Criteria: - Subjects who had received 3 doses of Infanrix hexa™ or Infanrix-IPV/Hib™ in study NCT00307034. - Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) LAR(s) can and will comply with the requirements of the protocol. - A male or female subject aged 5 years at the time of study entry. - Written informed consent obtained from the parent(s)/LAR(s) of the subject. - Healthy subjects as established by medical history and clinical examination before entering into the study. Exclusion Criteria: - Child in care. - Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. - Use of any investigational or non-registered product within 30 days prior to blood sampling. - Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, and Hib vaccination or disease since the study NCT00307034, with the exception of hepatitis B vaccination in the DTPa-IPV/Hib group. - Administration of immunoglobulins and/or any blood products within the 3 months prior to blood sampling. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. - Family history of congenital or hereditary immunodeficiency.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Blood Sampling
A blood sample will be taken at 5 years of age, after vaccination in the primary study.

Locations

Country Name City State
Norway GSK Investigational Site Morvik
Norway GSK Investigational Site Oslo
Sweden GSK Investigational Site Örebro
Sweden GSK Investigational Site Umeå

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Norway,  Sweden, 

References & Publications (1)

Silfverdal SA, Assudani D, Kuriyakose S, Van Der Meeren O. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Hum Vaccin Immunother. 2014;10(10):2795-8. doi: 10.4161/21645515.2014.970494. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T). A seroprotected subject is a subject with anti-D/anti-T antibody concentrations greater than (=) or equal to 0.1 international units per milliliter (IU/mL) At Day 0
Primary Concentrations of Antibodies Against Anti-D and Anti-T Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL). At Day 0
Primary Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Antifilamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations =5 ELISA Units Per Milliliter (EL.U/mL). Cut-off values assessed were greater than or equal to 5 ELISA units per millilitre (EL.U/mL) in the sera of subjects seronegative before vaccination. At Day 0
Primary Concentrations of Antibodies Against Anti-PT, Anti-FHA and Anti-PRN. Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL). At Day 0
Primary Number of Seroprotected Subjects Against Anti-hepatitis B Surface Antigen (Anti-HBs). Seroprotection = anti-HBs antibody concentration = 10 milli-international units per milliliter (mIU/mL). At Day 0
Primary Concentrations of Antibodies Against Anti-HBs. Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL). At Day 0
Primary Number of Seroprotected Subjects Against Anti-polyribosyl Ribitol Phosphate (Anti-PRP). A seroprotected subject is a subject with anti-PRP antibody concentrations = 0.15 micrograms per milliliter (µg/mL) At Day 0
Primary Concentrations of Antibodies Against Anti-PRP. Concentrations are presented as geometric mean concentrations (GMCs), expressed in micrograms per millilitre (µg/mL). At Day 0
Primary Number of Subjects With Serious Adverse Events (SAEs). Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. During the entire study period (up to Day 46)
Primary Number of Subjects With Anti-HBs Antibody Concentrations = 6.2 mIU/mL Cut-off values assessed were greater than or equal to 6.2 milliinternational units per millilitre ( mIU/mL) in the sera of subjects seronegative before vaccination. At Day 0
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A